Cardiology

PTSD was associated with a 3-fold increased risk of all-cause mortality or a major heart event in 12 months following cardiac arrest.

The updated cholesterol guidelines continue to emphasize a healthy lifestyle for people of all ages and the need for personalized treatment plans. They also lay out a path for escalating treatment when statins aren’t sufficient.

In visits with overweight or obese children with high blood pressure, pediatricians either provide no communication about BP or unclear or dismissive statements, unless SBP is ≥120 mmHg.

Data from a new study indicate that trauma is an independent risk factor for cardiovascular disease in sexual minority women, suggesting it should be screened for as a risk factor in this population.

Investigators have found an association between opioid use and cardiovascular mortality.

Not sure what’s been recalled, withdrawn from the market, or had safety updates? Catch up on the US Food and Drug Administration’s (FDA's) recalls and safety news from this past week.

Who is the best candidate for invasive treatment in the GERD population?

The FDA has approved Johnson & Johnson’s canagliflozin (INVOKANA) for patients with type 2 diabetes who have established cardiovascular disease in order to reduce the risk of major adverse cardiovascular events, such as heart attack, stroke, or death.

Patients with renal disease are poorly represented in studies of treatment for STEMI but, a new study finds, are at much greater risk for MACE and death.  

Statistical analysis reveals cardiac effects of individual antiretrovirals in combination treatments for children infected with HIV perinatally.

Along with sports cardiology and pediatric cardiology, Robert Battle specializes in treating patients with hypertrophic cardiomyopathy, the most common genetic cardiovascular disorder.

The new Medtronic device is capable of repairing thoracic aortic aneurysms, blunt thoracic aortic injuries, penetrating atherosclerotic ulcers, intramural hematomas, and aortic type B dissections.

Though new therapies are still in the distant future, advances in diagnosis may be on the horizon.

Distinguishing pulmonary arterial hypertension in patients is a difficult early diagnosis. But seeking out a combination of unexplained symptoms is a good first step.

Either one is fine – the point is to make sure the practice stays a step ahead of the next new drug class causing the problem.